• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Review on Niosomes - a Novel Approach for Drug Targeting
  • VIEWS 839
  • PDF 159

Journal of Pharmaceutical Research

Year: 2015, Volume: 14, Issue: 1, Pages: 20-25

Original Article

Review on Niosomes - a Novel Approach for Drug Targeting

Abstract

Purpose: This is a general review on niosome as drug carrier, which improves the bioavailability of drugs, increases penetration through skin, releases drug in a controlled or sustained manner, and used for targeting of drugs to speci?c sites in the body.Approach: Niosomal drug delivery system can be considered as an emerging novel drug delivery system, which consists of microscopic non-ionic vesicles composed of non-ionic surfactants. These are biodegradable, relatively nontoxic, more stable and inexpensive, and an alternative to liposomes. Methods of preparation, characterisation and application of niosomes have been reviewed.Findings: Niosome has potential to reduce the side effects of drugs and increase therapeutic effectiveness in various diseases. It can also be used as a carrier to deliver drugs topically.Conclusion: This review presents an overview of the types of niosomes, techniques of preparation of niosome, characterisation and their applications.

References

  • Yie W Chien. Novel Drug Delivery System, 2nded.New York: Marcel Dekker Inc; 1992. p. 1-42.
  • Tsuchihashi M, Harashima H, Kiwada H.Development of pharmacokinetic pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating leptosomes in mice using peritoneal. J control Rel. 1999;61:919.
  • Biju SS, Telegaonar S, Mishra PR, Khar RK. Vesicular system: an overview. Ind J Pharm Sci. 2006;68:141-53.
  • Vedhahari BN, Chitra KP, Bhimavarapu R, Karunakaran P, Muthukrishnan N, Rani B, et.al Novel technologies: A weapon against tuberculosis. Ind J Pharmacol. 2010;6:338-344.
  • Verma S, Singh SK, Navneet S, Mathur P, Valecha V. Nanoparticle vesicular systems: a versatile tool for drug delivery. J Chem Pharm Res. 2010; 2(2):496-509.
  • Baillie AJ, Coombs GH, Dolan TF, Laurie J. Nonionic surfactant vesicles, niosomes as delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharmacol. 1986; 38:502-5.
  • Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochem Biophys Acta. 1985;816: 294-302.
  • Raja RA, Chandrashekhar G, Pillai GK, Udupa N. Antiin?ammatory activity of niosome encapsulated diclofenac sodium with tween -85 in arthitic rats. Ind J Pharmacol. 1994;26:46-48.
  • Rogerson A, Cummings J, Willmott N, Florence AT. The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol. 1988;40:337-42.
  • Jayaraman SC, Ramachandran C, Weiner N Topical delivery of erythromycin from various formulations: an in vivo hairless mouse study. J Pharm Sci. 1996;85:1082-84.
  • Hao Y, Zhao F, Li N, Yang Y, Li K. Studies on a high encapsulation of colchicines by a noisome system. Int J Pharm. 2002;244:73-80.
  • Karim KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M. Niosome: a future of targeted drug delivery systems. J Adv Pharm Tech Res. 2011;62:122.
  • Chauhan S, Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant vesicles. J Pharm Pharmacol. 1989;41:46.
  • Blazek Welsh AI, Rhodes DG. SEM imaging predicts quality of niosomes from maltodextrinbased proniosomes. Pharm Res. 2001;18:65661.
  • Kumar AP, Lal J, Jaiswal A, Singh V. Review of niosomes as novel drug delivery system. Int Res J Pharm. 2011; 2(5):61-65.
  • Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, et al. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B: Biointerfaces. 2003;30:129-38.
  • Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol. 1985;37:37-42.
  • Kreuter J. Colloidal drug delivery system of noisome. New York: Marcel Dekker Inc; 1994. p 66-73.
  • Gregoriadis G, Florence AT. In: Liposome technology. Boca Raton, CRC Press, 1993; 2:165.
  • Yoshioka T, Stermberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sobitan monoesters (Span 20, 40, 60, and 80) and a sorbitan triester (Span 85). Int J Pharm. 1994; 105:1-6.
  • Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv. 2002;54: 131-55.
  • Sakthivel M, Kannan K, Manavalan R, Senthamarai R. Formulation and in vivo evaluation of niosom escontaining oxcarbazepine. J Pharm Sci and Res. 2013;5(1):8-11.
  • Arunothayanun P, Bernard MS, Craig DM, Uchegbu IF, Florence AT. The effect of processing variable so nthephysical l characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyldiglycerol ether. Int J Pharm. 2000;201:7-14.
  • Uchegbu FI, Vyas PS. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33-70.
  • Muzzalupo R, Tavano L, Lai F, Picci N. Niosomes containing hydroxyl additives as percutaneous penetration enhancers: effect on the transdermal delivery of sulfadiazine sodium salt. Colloids and Surfaces: B Biointerfaces. 2014;123:207-212.
  • Tarekegn A, Joseph NM, Palani S, Zacharia A, Ayenew Z. Niosomes in targeted drug delivery: some recent advances. Int J Phar Sci Res. 2010; (9):1-8.
  • Stafford S, Ballie AJ, Florence AT. Drug effect on the size of chemically de?ned nonionic surfactant vesicles. J Pharm Pharmacol. 1988;(26):40.
  • Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol. 1988;40:161-65.
  • Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv.2003;10:51-62.
  • Brewer JM and Alexander JA. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology. 1992; (75):570-75.
  • Manosroi A, Chankhampan C, Manosroi W, Manosroi J. Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment. Eu J Pharma Sci. 2013;48:474-483.
  • Sheena IP, Singh UV, Kamath R, Uma DP, Udupa N. Niosomal withaferin A with better antitumour ef?cacy. Indian J Pharm Sci. 1998;60:45-48.
  • Moser T, Marchand-Arvier M, Labrude P, Vigneron C. Hemoglobin niosoms. Pharm Act Helv. 1990;65:82-92.
  • Korkmaz M, Ozer AY, Hincal AA. �DTPA niosomes in diagnostic imaging� ed. by Uchegbu I F. Singapore: Harwood Academic Publishers; 2000. p. 227-42.
  • Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide.J Pharm Pharm Sci. 2002;5(3):220-5.
  • Bansal S, Aggarwal G, Chandel P, Harikumar SL. Design and development of cefdinir niosomes for oral delivery. J Pharm Bioall Sci.2013;5(4):318-25.
  • Chaudhari SP, Chatur VM. Development of valproic acid niosomal in situ nasal gel formulation for epilepsy. Ind J Pharma Edu Res.2013; 16(3):31-41.

DON'T MISS OUT!

Subscribe now for latest articles and news.